Protamine is used after cardiopulmonary bypass was stopped in order to reverse the anticoagulant effects of heparin administered during open-heart operations. Adverse hemodynamic responses to protamine are common, ranging from minor perturbations to cardiovascular collapse. The aim of the present study was to investigate whether a prostacyclin is effective in the treatment of protamine-mediated acute pulmonary hypertension and right ventricular failure in the perioperative period of isolated coronary artery bypass grafting (CABG) operations. In sixty-eight (1.78%) of 3800 patients who underwent isolated CABG, acute pulmonary hypertension and right ventricular failure developed during or following the protamine infusion. These 68 patients were included in the study and were randomized into two groups. Thirty-eight of the patients received prostaglandin I 2 (PGI 2 ), norepinephrine and dopamine (PGI 2 group), whereas 30 patients received nitroglycerin, norepinephrine and dopamine (control group). Hemodynamic data were recorded before and after the above drug combinations. The mean value of left ventricle ejection fraction significantly increased (p < 0.05) and mean values of central venous pressure, pulmonary artery systolic and diastolic pressure, pulmonary capillary wedge pressure and pulmonary vascular resistance significantly decreased (p < 0.05) in the PGI 2 group. The mean value of pulmonary capillary wedge pressure significantly decreased (p < 0.05) and the mean value of central venous pressure significantly increased (p < 0.05) in the control group. In conclusion, prostacyclin (PGI 2 ) is effective in the treatment of protamine-mediated acute pulmonary hypertension and right ventricular failure in the perioperative period in isolated CABG operations. This finding may be an important contribution to the treatment of severe protamine complications during open-heart operations.
Protamine sulfate is a polycationic peptide that is used in order to reverse the anticoagulant effects of heparin (Viaro et al. 2002) . In openheart surgery, protamine is used after cardiopulmonary bypass (CPB) was stopped. However, the side effects of protamine show a wide spectrum ranging from minimal cardiovascular deterioration to grave cardiovascular collapse which can threaten the life of the patient (Stewart et al. 1984; Levy et al. 1986 Levy et al. , 1989 Pearson et al. 1992) . Acute pulmonary hypertension and right ventricular dysfunction, for instance, can occur as devastating complications of protamine infusion.
Once these complications develop, immediate abortion of intravenous infusion of protamine, readministration of heparin and the recommencement of CPB are the safe and most-applied initial therapeutics. However, there is yet insufficient literature to define therapeutic agents for further treatment.
The purpose of the current study was to investigate the efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension in the perioperative period of isolated coronary artery bypass grafting (CABG) operations.
METHODS

Subjects.
Between January 1991 and December 2004, 3,800 consecutive patients underwent isolated CABG operations in three hospitals in Turkey. In 68 (1.78%) of 3,800 patients, acute pulmonary hypertension and right ventricular failure developed during or following the protamine infusion intraoperatively. The patients, in whom protamine reactions occured, were included in the study. They were 37 (54%) men and 31 women (46%), and the mean age of the patients was 53 ± 3.1. Coronary arteriography was performed for the diagnosis of the coronary artery disease during cardiac catheterization in all patients in the preoperative period. Angiographic evaluation of the left subclavian artery and left internal mammary artery (LIMA) was done to eliminate any atherosclerotic lesion in the subclavian artery, which may cause subclavian steal syndrome (Cınar et al. 2004) . The use of aspirin had been ceased in all patients one week prior to the operation. Inclusion criteria of the study were intraoperative development of pulmonary hypertension and right ventricular failure during or following intravenous infusion of protamine. Patients with heart valve disease and prior diagnosed pulmonary hypertension were excluded from the study. Table 1 presents the characteristics of the patients in the preoperative period. This research was conducted with approval of the ethic committee of the School of Medicine, Suleyman Data are presented as mean ± S.D. MI, number of the patients with previous myocardial infarction; Performance score, performance score of the left ventricule on cardiac catheterization; LMCA, left main coronary artery; LAD, left anterior descending; 2 V, 2 vessels; 3 V, 3 vessels; OA, oral antidiabetics; NPH, neutral protamine Hagedorn insulin; NYHA, New York Heart Association; EF, left ventricle ejection fraction.
Demirel University, and all patients signed informed consent prior to enrollment.
Operative technique. Standard anesthetic techniques and anesthetics were used in all patients. A SwanGanz catheter was inserted through the right internal jugular vein after anesthesia induction for hemodynamic measurements. Following a standard median sternotomy, the ascending aorta was cannulated for arterial inflow and the right atrial appendage was cannulated with twostage cannula for venous uptake. A cardioplegic tack was introduced into the aortic root proximal to the aortic cannulation site for antegrade cardioplegic delivery. A purse-string suture was passed in the right atrium, and the retrograde cannula was placed into the coronary sinus for retrograde cardioplegic delivery. Heparin was given at a dose of 3 mg/kg for systemic anticoagulation effect and CPB was established. Myocardial protection was maintained using initially cold (0-4°C) crystalloid cardioplegia solution followed by cold blood (10°C) cardioplegia and finally warm blood (37°C) cardioplegia as described in "Integrated Cardioplegia Protocol." Mild systemic hypothermia (32°C) was applied. The left internal mammary artery (LIMA) was anastomosed to the left anterior descending (LAD) coronary artery and saphenous venous grafts were used for bypass to the other coronary arteries. Both single-clamp and side-clamp techniques were used for construction of proximal anastomoses. After cessation of CPB, removing the venous cannulas and confirmation that hemorrhage was not severe, the heparin was reversed through the use of intravenous protamine, in a ratio of 1.5 mg of protamine to 1 mg of circulating heparin.
Treatment of protamine adverse reactions. Pulmonary hypertension was defined as follows: > 40 mmHg pulmonary artery systolic pressure, > 20 mmHg pulmonary artery diastolic pressure, > 20 mmHg pulmonary artery wedge pressure and > 250 (dyn × sec) / cm 5 pulmonary vascular resistance. Right ventricular failure was described on inspection as determination of diminished right ventricular contractions with unaffected left ventricular contractions. When pulmonary hypertension and right ventricular dysfunction developed, intravenous infusion of protamine was immediately aborted. Heparin was given at a dose to ensure an activated clotting time (ACT) of more than 450 seconds and CPB was restarted in necessitating patients. When right ventricular distension was noted, 200-250 ml of blood was drained back to the heart-lung machine to decrease over-volume. In addition to these measures, patients were randomized into two groups, who were treated with two different treatment schemes. One group (n = 38) received intravenous (IV) injection of prostaglandin I 2 (PGI 2 ) (Flolan ® , GlaxoSmithKline, Middlesex, UK) (2 ng/kg/min), norepinephrine (4 μ g/kg/min) and dopamine (2.8 μ g/kg/ min). The control group (n = 30) received IV injection of nitroglycerin (5 μ g/kg/min), norepinephrine (4 μ g/kg/ min) and dopamine (2.8 μ g/kg/min). These drugs were administered directly into the pulmonary artery via distal lumen of the Swan-Ganz catheter. Rapid administration of protamine was avoided and corticosteroids were used to avoid recurrence of protamine reactions after termination of secondary CPB. Hemodynamic data. Systolic systemic arterial pressure (SSAP) (mmHg), diastolic systemic arterial pressure (DSAP) (mmHg), heart rate (HR) (per minute), cardiac output (CO) (L/min), cardiac index (CI) (L/min/ m²), pulmonary artery systolic and diastolic pressures (PASP) and (PADP) (mmHg), pulmonary artery capillary wedge pressure (PCWP) (mmHg), left ventricle ejection fraction (EF) (%), central venous pressure (CVP) (mmHg) and pulmonary vascular resistance (PVR) ([dyn × sec]/cm 5 ) were recorded in all patients. PVR was calculated using the following formula: PVR = 80 × (MPAP-PCWP) / CO (PVR, pulmonary vascular resistance; MPAP, mean pulmonary artery pressure; PCWP, pulmonary artery wedge pressure; CO, cardiac output).
All measurements except EF were done through the Swan-Ganz catheter. EF was measured by transthoracic echocardiography in the preoperative period and by transesophageal echocardiography in the operating theater. In order to define severity of protamine reactions, hemodynamic data were recorded just after CPB had stopped (time 1 = t1) and at the time protamine reactions developed (time 2 = t2). In order to define the efficiency of the treatment schemes, hemodynamic measurements were done just after the secondary CPB had stopped (time 3 = t3) and six hours after the starting of IV infusions of drugs according to treatment schemes. Additionally, the need for restarting CPB, secondary CPB duration (min), intraaortic balloon pump usage, intensive care unit stay (days) and extubation duration (hours) were recorded in all patients.
Analysis of data
Data are expressed as mean ± S.D. or percentages. Differences within and among groups were analyzed by the Wilcoxon signed rank test and Mann-Whitney's U-test. All tests were two tailed and a probability value of p < 0.05 was considered significant. Statistical analysis was done with SPSS software (version 6.1, Chicago, Illinois, USA).
RESULTS
Protamine reactions
Termination of CPB was uneventful in 3,800 cases. However, protamine adverse effects developed in 68 patients during or following protamine infusion. Pulmonary artery pressures (PASP, PADP, PCWP) and PVR abruptly and significantly increased in all patients (Tables 2 and 3) (p < 0.05). Right heart distension and tendency to bradycardia developed. The right ventricular contractions decreased whereas the left ventricular contractions remained unaffected in the early minutes. HR and EF significantly decreased whereas CVP significantly increased in both groups (p < 0.05). Restarting of CPB was required in 14 patients (39%) in the PGI 2 group, whereas in all patients in the control group. Mean durations of secondary CPB were 17 ± 7.8 and 38 ± 12 minutes in the PGI 2 group and in the control group, respectively and the difference between the groups was statistically significant (p < 0.05).
Treatment of the reactions
PGI 2 group. Hemodynamic data after CPB, at protamine reactions and after reCPB are shown in Table 2 . PASP, PADP, PVR and PCWP significantly decreased following administration of drug combination (p < 0.05). Mean values of PASP, PADP, PVR and PCWP were 24 ± 2.1 mmHg, 10 ± 0.9 mmHg, 224 ± 18.6 (dyn × sec)/cm 5 and 16 ± 2.1 mmHg, respectively, six hours after the starting of IV infusion of drugs. Right heart distension diminished and right ventricular contractions improved following administration of drug combination. SSAP, DSAP, HR, CO and CI slightly increased (p > 0.05), CVP significantly decreased (p < 0.05) whereas EF significantly increased (p < 0.05). Mean values of SSAP, DSAP, HR, CO, CI, Data are presented as mean ± S.D. SSAP, systolic systemic arterial pressure; DSAP, diastolic systemic arterial pressure; HR, heart rate; CO, cardiac output; CI, cardiac index; PASP, pulmonary artery systolic pressure; PADP, pulmonary artery diastolic pressure, PCWP, pulmonary artery wedge pressure; CVP, central venous pressure; EF, left ventricle ejection fraction; PVR, pulmonary vascular resistance; and reCPB, secondary CPB. a p < 0.05 compared to after CPB; b p < 0.05 compared to after CPB or after reCPB; c p < 0.05 compared to after CPB or after reCPB; d p < 0.05 compared to after CPB or after reCPB; e p < 0.05 compared to after CPB or after reCPB; f p < 0.05 compared to after CPB or after reCPB; g p < 0.05 compared to after CPB or after reCPB.
EF and CVP were 125 ± 15.6 mmHg, 75 ± 14.8 mmHg, 78 ± 3.6 per minute, 4.2 ± 1.2 L/min, 2.8 ± 0.4 L/min/m², 46 ± 4.1% and 8 ± 0.7 mmHg, respectively, six hours after the starting of IV infusion of drugs.
Control group. Hemodynamic data after CPB, at protamine reactions and after reCPB are shown in Table 3 . PASP, PADP and PCWP slightly decreased (p > 0.05) and PVR significantly increased (p < 0.05) following administration of drug combination. Mean values of PASP, PADP, PVR and PCWP were 42 ± 2.8 mmHg, 22 ± 2.9 mmHg, 568 ± 44.5 (dyn × sec)/cm 5 and 22 ± 1.7 mmHg, respectively, six hours after the starting of IV infusion of drugs. SSAP, DSAP, HR, CO, CI and EF slightly increased (p > 0.05) and CVP significantly increased (p < 0.05) following administration of drug combination. Mean values of SSAP, DSAP, HR, CO, CI, EF and CVP were 110 ± 7.6 mmHg, 70 ± 6.7 mmHg, 72 ± 1.7 per minute, 3.8 ± 1.4 L/min, 2.4 ± 0.6 L/min/m², 38 ± 2.9% and 14 ± 1.6 mmHg, respectively, six hours after the starting of IV infusion of drugs. The parameters that altered statistically significant following administration of the drug combinations in each group are shown in Table 4 .
Outcome of the patients
Intraaortic balloon pumping was necessary in four patients in the PGI 2 group and in five patients in the control group. Mean duration of intensive care stay was 2.4 ± 1.2 and 4.2 ± 1.7 days in the PGI 2 group and in the control group, respectively. Mean duration of extubation was 8 ± 1.1 and 14 ± 2.1 hours in the PGI 2 group and in the control group, respectively. In total five patients died in the intraoperative and postoperative periods. There were two intraoperative deaths due to catastrophic pulmonary hypertension, all of which were in the control group. There were three postoperative deaths: one patient in the PGI 2 group and two patients in the control group. One patient in the PGI 2 group died due to pulmonary complications on postoperative third day. Two patients in the control group died due to multi-organ failure on postoperative fourth and fifth days, respectively.
DISCUSSION
The question addressed by the present study was whether prostacyclin is effective in the treatment of protamine-mediated acute pulmonary hypertension and right ventricular failure in the perioperative period in isolated CABG operations. The main finding of the study is that prostacyclin is effective in the treatment of these protaminemediated complications in the perioperative period in isolated CABG operations.
Protamine adverse reactions usually have three different categories: systemic hypotension, anaphylactoid reactions and catastrophic pulmonary vasoconstriction (Viaro et al. 2002 ). The precise mechanism that explains protamine-mediated systemic hypotension is unknown. However, diminished peripheral vascular resistance may be a causative factor (Marin-Neto et al. 1979; Masone et al. 1982; Shapira et al. 1982; Milne et al. 1983; Paulo et al. 1995) . In our study, mean values of systemic arterial pressure, heart rate, cardiac output, cardiac index and left ventricle ejection fraction decreased and central venous pressure increased following protamine reactions. The differences for mean values of SSAP, DSAP, CO and CI were not statistically significant in either group, and this may suggest a slight systemic hypotension. Differences for mean values of HR, EF and CVP were statistically significant (p < 0.05) and this may suggest diminished right ventricular contractions and severe bradycardia. The majority of anaphylactic/anaphylactoid reactions are associated with complement activation and the release of anaphylotoxins complement 3a (C3a) and 5a (C5a) (Hobbhahn et al. 1991) . Morel et al. (1987) found increased plasma levels of tromboxane B2 (TxB2) and C5a levels in patients who developed acute pulmonary hypertension and systemic hypotension following right atrial protamine injection. Anaphylactoid reactions result in catastrophic pulmonary vasoconstriction which induces right and eventually global ventricular failure (Hobbhahn et al. 1991) . In our study, pulmonary artery pressures and PVR increased in all patients during protamine infusion. However, differences were statistically insignificant in both groups and this may suggest a mild form of an anaphylactic reaction rather than a catastrophic pulmonary vasoconstriction except in two patients in the control group.
When protamine-mediated right ventricular failure and acute pulmonary hypertension occurs, the basis of the treatment is to reduce pulmonary artery pressure and maintain systemic arterial pressure and right ventricular contractility. Vasodilators such as nitroglycerin and phosphodiesterase inhibitors may be useful in this setting. We used dopamine for bradycardia, whereas norepinephrine was given to fight acute peripheral vasodilation caused by abrupt decrease of system-ic vascular resistance. In addition, nitric oxide (NO) is an important endothelium-derived relaxing factor and produces profound relaxation of vascular smooth muscle. Fratacci et al found that inhaled NO is a selective pulmonary vasodilator that can prevent thromboxane-induced pulmonary hypertension during the heparin-protamine reaction in lambs and can do so without causing systemic vasodilation (Fratacci et al. 1991) .
Prostacyclin (PGI 2 ) and TxA2 are the predominant cyclooxygenase products of arachidonic acid. PGI 2 is mainly formed by vascular endotelium and dilates both bronchial and vascular smooth muscle whereas TxA2 is formed by platelets and constricts bronchial and vascular smooth muscle. Disturbance of the balance between prostaglandin and TxA2 in favor of TxA2 by protamine may be considered a causative factor in the etiology of acute pulmonary vasoconstriction and consequently acute pulmonary hypertension. It was the basis for adding PGI 2 to norepinephrine and dopamine in therapy scheme in our study.
When t 2 and t 3 were compared in the PGI 2 group, there was a statistically significant difference for all pulmonary pressures and PVR (p < 0.05). This may suggests that PGI 2 effectively decreased pulmonary pressures and PVR. However, when same comparison was done, there was a statistically significant difference for only PVR (p < 0.05). This may suggest that nitroglycerin is also an useful agent but is not as effective as PGI 2 in the fight against acute pulmonary hypertension.
The number of patients who required restarting of CPB was lower in the PGI 2 group than in the control group (38% vs 100%). The mean duration of secondary CPB was shorter in the PGI 2 group than in the control group. These indicate the possible beneficial effects of PGI 2 on lower necessity of secondary CPB and shorter CPB durations. Additionally, mean duration of intensive care stay and mean duration of extubation were shorter in the PGI 2 group than in the control group, indicating a more favorable postoperative course in the PGI 2 group.
A few potential pharmacologic agents are under development as alternatives to protamine.
Platelet factor 4 (PF4) is a naturally occurring protein synthesized in megakaryocytes and eventually stored in the alpha granules of platelets for later release. Although the complete physiologic role of PF4 is unknown, it is highly effective for the neutralization of heparin anticoagulation. Several preliminary animal studies and trials using blood obtained from cardiopulmonary bypass circuits suggested recombinant PF4 would be an effective alternative to protamine (Shanberge et al. 1987; Cook et al. 1992; Bernabei et al. 1995; Dehmer et al. 1995; Levy et al. 1995; Mixon et al. 2004) . Heparinase I, a specific enzyme that inactivates heparin, is another possible alternative to protamine (Michelsen et al. 1996) . Heres et al. (2001) found that heparinase-I successfully restored activated coagulation time with no adverse hemodynamic events in patients undergoing coronary artery surgery with cardiopulmonary bypass in an open-label dose-determining trial. Finally, heparin-binding filters have been also considered as an alternative to protamine but additional human studies are needed to demonstrate the safety and efficacy of the method (Ma et al. 1992 ).
In conclusion, our findings suggest that prostacyclin (PGI 2 ) is effective in the treatment of protamine-mediated acute pulmonary hypertension and right ventricular failure during the perioperative period in isolated CABG operations. However, additional data from further studies is required to clarify the role of PGI 2 in the treatment of these complications.
